David Brassat

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 97 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology

Published: June 14, 2025

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Journal: Annals of clinical and translational neurology

Published: April 01, 2025

Natural history of adult-onset metachromatic leukodystrophy.

Natural history of adult-onset metachromatic leukodystrophy.

Journal: Journal of neurology

Published: December 20, 2024

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.

Journal: Annals of neurology

Published: May 24, 2024

Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.

Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.

Journal: European journal of neurology

Published: May 07, 2024

Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Journal: The Journal of experimental medicine

Published: October 28, 2022

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.

Journal: Frontiers in neurology

Published: August 10, 2022

Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Journal: The Journal of experimental medicine

Published: April 13, 2022

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 30, 2020

Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.

Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 03, 2020

Showing 1-12 of 97

Last Updated: 09/26/2026